Is the White House wobbling on psychedelics? Next few weeks could be critical for psychedelic drug approvals

Psychedelics policy in the White House may be shifting just as the industry is approaching key FDA milestones. The piece points to Compass Pathways reporting positive Phase 3 psilocybin trial results and raising capital, framing this as leverage for an FDA application later in 2026. It then contrasts an earlier window of political openness with what the author characterizes as growing silence and behind-the-scenes resistance. Examples include alleged obstacles tied to special approval mechanisms and commentary suggesting MAGA-aligned skepticism. The author argues that the coming weeks could determine whether pro-psychedelic momentum becomes practical approvals or repeats past setbacks like the 1970s shutdown, later MDMA criminalization, and the stalled federal psychedelic task force. It also outlines four suspected reservation areas from the White House and the Christian Right to industry competition around established treatments like Spravato.